No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.8x · 10Y median 73.1x · 22nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:42:40.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Onconetix, Inc. (ONCO) stock was $0.68 as of Oct 6, 2026, 2:37 PM EDT, up 1.14% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -99.5% · 3-year avg -97.9%/yr
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide.
Biotechnology · Cincinnati, OH
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-45050.00
Revenue Est.
$17455.00
Last Quarter Results
EPS
$-52700.03
vs Estimate
$-32300.02
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ONCO | $2.44M | $0.68 | +1.14% | -99.55% | N/A | N/A | N/A |
| 2MBRX | $2.37M | $0.44 | -6.82% | -95.81% | -78.48% | -64.00% | vs ONCO |
| 3SHPH | $2.36M | $4.04 | +0.62% | -90.95% | N/A | N/A | vs ONCO |
| 4CELZ | $2.34M | $0.91 | -1.29% | -71.43% | -57.96% | -72.19% | vs ONCO |
| 5JAGX | $2.33M | $5.36 | +13.32% | N/A | N/A | N/A | vs ONCO |
| 6FBLG | $2.56M | $1.22 | +3.38% | -89.14% | N/A | N/A | vs ONCO |
forward FY estimate
N/A
$17120.00
vs Estimate
$17120.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.68
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-45050.00 | $-45050.00 | $-45050.00 | 1 |
| Quarter ending Dec 2026 | $-45050.00 | $-45050.00 | $-45050.00 | 1 |
| Quarter ending Mar 2027 | $-34850.00 | $-34850.00 | $-34850.00 | 1 |
| Quarter ending Jun 2027 | $-20400.00 | $-20400.00 | $-20400.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-200600.00 | $-200600.00 | $-200600.00 | 1 |
| FY 2027 | $-214200.00 | $-214200.00 | $-214200.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $17455.00 | $17455.00 | $17455.00 | 1 |
| Quarter ending Dec 2026 | $17797.00 | $17797.00 | $17797.00 | 1 |
| Quarter ending Mar 2027 | $18146.00 | $18146.00 | $18146.00 | 1 |
| Quarter ending Jun 2027 | $18502.00 | $18502.00 | $18502.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $881218.00 | $881218.00 | $881218.00 | 1 |
| FY 2027 | $952384.00 | $952384.00 | $952384.00 | 1 |
